Condition: Tricuspid Regurgitation · Sponsor: Trisol Medical
The objective of this early feasibility study is to gain early clinical insight into Trisol system safety and performance to treat patients with moderate or greater tricuspid regurgitation (TR).
This description comes directly from the study's public registry record.
Ron Davidson, B. Sc., MBA · +972 528998866 · rond@trisol-medical.com
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Piedmont Heart Institute | Atlanta, Georgia, United States | Recruiting |
| Columbia University Medical Center/NYPH | New York, New York, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Main Line Health / Lankenau Institute for Medical Research | Wynnewood, Pennsylvania, United States | Not Yet Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
| University of Virginia Cardiology | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04905017